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Abstract
The continued spread of highly pathogenic avian influenza (HPAI) H5N1 virus underscores the importance of effective
antiviral approaches. AVFluIgG01 is a potent and broad-reactive H5N1-neutralizing human monoclonal antibody (mAb)
showing great potential for use either for therapeutic purposes or as a basis of vaccine development, but its antigenic
epitope and neutralization mechanism have not been finely characterized. In this study, we first demonstrated that
AVFluIgG01 targets a novel conformation-dependent epitope in the globular head region of H5N1 hemagglutinin (HA). By
selecting mimotopes from a random peptide library in combination with computational algorithms and site-directed
mutagenesis, the epitope was mapped to three conserved discontinuous sites (I-III) that are located closely at the three-
dimensional structure of HA. Further, we found that this HA1-specific human mAb can efficiently block both virus-receptor
binding and post-attachment steps, while its Fab fragment exerts the post-attachment inhibition only. Consistently,
AVFluIgG01 could inhibit HA-mediated cell-cell membrane fusion at a dose-dependent manner and block the acquisition of
pH-induced protease sensitivity. These results suggest a neutralization mechanism of AVFluIgG01 by simultaneously
blocking viral attachment to the receptors on host cells and interfering with HA conformational rearrangements associated
with membrane fusion. The presented data provide critical information for developing novel antiviral therapeutics and
vaccines against HPAI H5N1 virus.
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Introduction
Highly pathogenic avian influenza (HPAI) H5N1 viruses
continue to spread among poultry and have frequently broken
the species barrier and transmitted to humans. As of February
2012, there were 583 confirmed human H5N1 infections from 15
countries, with a fatality rate of .59% (344), alarming that the
consequences of a H5N1 pandemic could be catastrophic.
Therefore, many efforts have focused on the development of
effective therapeutics and vaccines in preparedness. Of them the
neutralizing antibody-based strategies have been particularly
explored.
The viral hemaglutinin (HA) surface glycoprotein of influenza A
viruses is not only responsible for binding to cell receptor but also a
primary target of neutralizing antibodies. It is initially synthesized
as a precursor polypeptide (HA0) and subsequently cleaved by
cellular proteases into disulfide-linked HA1 and HA2 subunits.
The N-terminal HA1 subunit forms a globular head region that
contains the receptor-binding site (RBS), whereas the membrane
anchoring HA2 subunit forms a helix-rich stem that contains a
relatively conserved fusion peptide. The HA protein of influenza A
viruses evolves with great genetic diversity and can be classified
into 16 distinct subtypes. However, few of the 16 subtypes have
been finely characterized with respect to their antigenic structures.
In the early 1980s, the location and structure of HA epitopes was
first characterized in the three-dimensional (3D) model of the H3
subtype [1]. Four antigenic sites were demonstrated (A, B, C, and
D), and a fifth (E) was later described. The H3 structure was used
to map the antigenic sites of H1 [2], H2 [3], and H5 [4] subtypes.
The H5 HA was antigenically mapped in greater detail after its
crystal structure was reported [5–7]. Prominently, the antibody
binding epitopes of the H5 HA are located exclusively in areas
corresponding to antigenic sites A and B of H3 HA and the
antigenic site Sa of H1 HA. Recently, Kaverin et al [8]
demonstrated that the HA antigenic structure of recent HPAI
H5N1 isolates differs substantially from that of low-pathogenicity
H5 strains described earlier and is rapidly evolving.
It is also noteworthy that previous epitope mapping of HA
protein were largely based on the virus escape mutants selected
by mouse monoclonal antibodies (mAbs), which might not
precisely predict the antigenic epitopes recognized by human
immune system [9]. The apparent success of passive immuno-
therapy of a H5N1-infected patient with convalescent plasma
emphasizes the importance of human antibodies in fighting
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neutralizing human mAbs as antiviral agents by various
approaches. Importantly, human mAbs can also be used to
map the antigenic epitopes of HA that stimulate humoral
immune responses during the natural infection of influenza
viruses and thus serve as an ideal basis for vaccine development.
Recently, Sun et al generated two H5N1-neutralizing human
mAbs, AVFluIgG01 and AVFluIgG03, by screening a phage
display library derived from a recovered patient infected with
highly pathogenic H5N1 viruses [12]. Previous studies showed
that AVFluIgG01 had a broad-spectrum anti-H5N1 activity and
its passive immunization could efficiently protect mice from a
lethal H5N1 virus infection [12]. In this study, we have focused
to characterize its antigenic epitope and neutralization mecha-
nism. Our data have demonstrated that AVFluIgG01 targets a
novel and conserved conformation-dependent epitope located in
the globular head region of HA and exerts its neutralizing
activity by simultaneously blocking viral attachment to the cell
receptors and interfering with HA conformational rearrange-
ments associated with membrane fusion.
Results
AVFluIgG01 Recognizes a Conformational Epitope within
HA1
Previous studies concluded that human mAb AVFluIgG01
targets a linear epitope within a sequence of the
116IIPKSSWSS
124
in the global head region of HA [12]. To better locate its epitope
residues, we synthesized a set of overlapping peptides that cover
full length HA and used in peptide-based ELISA (Fig. 1).
Disappointedly, AVFluIgG01 did not react with the peptide
110–127 that contains the
116IIPKSSWSS
124 sequence and any of
other overlapping and non-overlapping peptides, while it reacted
strongly with recombinant HA and HA1 proteins (Fig. 1A–1B).
This result implied that the epitope for AVFluIgG01 could not be
simply located within the
116IIPKSSWSS
124 motif. Therefore, we
tested the reactivity of AVFluIgG01 with a DTT-reduced HA in
comparison with the native HA. Fig. 1C shows that disulfide bond
reduction of HA protein could completely abolish the binding of
AVFluIgG01. Serving as a control antibody recognizing a
conformation-dependent epitope, AVFluIgG03 reacted with the
native but not reduced HA similarly. Severing as a control
antibody recognizing a linear epitope within HA2, 9G1G9 reacted
with both native and reduced HA proteins. These results indicated
that AVFluIgG01 was directed against a disulfide bond-dependent
conformational epitope expressed on the HA1 subunit.
Computational Prediction of AVFluIgG01 Epitope
We sought to decipher the binding sites of AVFluIgG01 by
selecting mimotopes from a random peptide phage display library,
as previously used to map conformation-dependent mAbs [13–14].
After 3 rounds of panning, 53 phage clones were isolated and the
amino acid sequences of their peptides were determined (Fig. 2A).
The specificity and relative affinity of the binding of these peptides
to AVFluIgG01 were tested in ELISA as described. From total of
selected 23 different mimotopes, we could not find apparent
consensus sequences or common sequence motifs that can deduce
epitopic HA residues. Therefore, we used two computational
methods, Mapitope and Pep-3D-Search, to predict the AV-
FluIgG01 epitope. Both searching algorithms are preferentially for
identifying discontinuous B-cell epitopes based on the 3D structure
of a protein antigen [15–16]. As shown in Fig. 2B–2C, the
Mapitope predicted a total 32 residues while the Pep-3D-Search
predicted 36 residues. All predicted residues are exclusively located
in the global head region of HA1 subunit. Notably, two patches of
residues (S121, W122, S123, S124, H125 and Y164, N165, T167,
N168, Q169) were predicted by both programs, suggesting an
involvement of these two sites for AVFluIgG01 binding.
Identification of the Epitope Residues by Mutagenesis
To identify the epitope residues critical for AVFluIgG01
binding, we generated a panel of 30 HA mutants carrying single
amino acid substitutions (Table 1). The wild-type (WT) and
mutated HA proteins were transiently expressed on the surface of
293T cells by transfection. The reactivity of AVFluIgG01 with
each HA mutant was examined by IFA and FACS assays. The
results are shown in Table 1 and Fig. 3. As a control for
expression, no mutations affected the binding ability of a human
mAb directed against the HA2 subunit. Prominently, substitutions
of W122 and T167 with alanine completely abolished the binding
of AVFluIgG01 to the HA expressed on the cell surface, while
substitutions of the residues I116, I117, P118, S123, and Y164
resulted in a dramatic loss of the reactivity. This result verified
these residues as critical sites for AVFluIgG01 binding. In
addition, mutations at N165 and N168 also substantially reduced
the reactivity of AVFluIgG01 with the expressed HA in the FACS
assay. The remaining substitutions had no significant effects on the
binding of both AVFluIgG01 and control antibodies.
Therefore, three discontinuous sites, designated site I (I116,
I117, P118), site II (W122, S123), and site III (Y164, T167) are
likely involved in the AVFluIgG01 epitope. In the 3D structure,
the epitope residues are adjacent to each other at the tip of the
membrane-distal globular domain of HA monomer, in close
proximity to the receptor-binding domain (Fig. 4). Importantly,
these amino acids are highly conserved among diverse H5N1
clades and subclades [12–13,17], underlying the broad-spectrum
H5N1-neutralizing activity by AVFluIgG01.
AVFluIgG01 Inhibits Both Virus Attachment and Post-
attachment Steps
Cell entry of influenza A viruses is mediated by its HA protein
through two steps [18]. First, the HA protein binds to the cell
receptor resulting in the endocytosis of virus into the host. Second,
the viral membrane fuses with the endosomal membrane to release
the viral RNA into the host cell. To explore the mechanism of
neutralization by AVFluIgG01, we first performed experiments to
know whether this mAb can inhibit the receptor-binding step. As
shown in Fig. 5A, the virus binding inhibition assay indicated that
AVFluIgG01 could efficiently inhibit HA-mediated virus binding
to the MDCK cells. Apparently, this inhibition was at a dose-
dependent manner (high, medium, and low). Fig. 5B shows an
inhibition curve with IC50 at 1.85 mg/ml. However, the Fab
fragment of AVFluIgG01 had no such inhibitory activity. As
expected, two control mAbs, AVFluIgG03 and CR6261 could not
inhibit the virus-receptor binding. It is known that AVFluIgG03
has no reactivity with the tested HA (A/H5N1/Vietnam/04) and
CR6261 targets a conserved epitope in the HA2 subunit [12,19].
Further, we studied whether AVFluIgG01 can inhibit the virus
after its attachment on the target cells. In the postattachment
neutralization assay, the HA pseudoviruses were allowed to absorb
to MDCK cells at 4uC and the unbound viruses were washed off.
Different concentrations of antibodies were then added to
determine if they can prevent the attached virus from entering
the target cells by membrane fusion. As shown in Fig. 6, both IgG
and Fab molecules of AVFluIgG01 mediated postattachment
inhibition at dose-dependent manners. They inhibited the HA
pseudoviruses with mean IC50 values at 2.02 and 1.63 mg/ml,
respectively. As control antibodies, AVFluIgG03 had no inhibitory
Epitope and Neutralization Mechanism of AVFluIgG01
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the previous reports [12,19].
Efficient Inhibition of Cell Fusion and Protease
Susceptibility
As was revealed above by the postattachment neutralization
assay, AVFluIgG01 might inhibit not only the receptor-binding
step but also the membrane fusion step. To directly evaluate
whether it is the case, we performed two cell fusion assays as
described in the materials and methods. In the first fusion assay,
the Vero cells were transfected with HA and induced for fusion by
low-pH in the presence or absence of AVFluIgG01 or a control
mAb. As shown in Fig. 7A, AVFluIgG01 did inhibit HA-mediated
cell-cell fusion. In the second fusion assay, we demonstrated that
AVFluIgG01 could inhibit the fusion between the HA-transfected
293T effector cells and MDCK target cells with a typical dose-
response curve. As a control, AVFluIgG03 had no such effects in
both systems.
AVFluIgG01 is a receptor-binding subunit (HA1)-specific mAb.
Why could it also inhibit HA-mediated cell membrane fusion? We
sought to ascertain its mechanism by a protease susceptibility
assay, in which the HA protein was exposed to a low-pH to trigger
a conformational change and acquire sensitivity to cleavage by
trypsin. Convincingly, the low-pH treated HA could be completely
digested by trypsin in the absence of AVFluIgG01 or its Fab
fragment (lane 5 in Fig. 8A and 8B). However, both formats of
antibodies were able to protect the HA from the degradation by
Figure 1. Reactivity of AVFluIgG01 with different HA antigens. A. Representative sequences of synthesized HA peptides (Viet04). B.
Reactivity of AVFluIgG01 with the recombinant HA or HA1 proteins (Viet04) and overlapping peptides in ELISA. C. Reactivity of AVFluIgG01 with the
native and reduced HA proteins (HK06) in ELISA. Synthesized peptides at 5 mg/ml or recombinant HA proteins at 1 mg/ml were used to coat 96-well
microtiter plates, and AVFluIgG01 or a control mAb was tested at a final concentration of 10 mg/ml.
doi:10.1371/journal.pone.0038126.g001
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binding of AVFluIgG01 or its Fab fragment can block the HA to
undergo a conformational change and thus render it resistant to
proteolysis.
Discussion
AVFluIgG01 is newly-isolated human mAb possessing potent
and broad neutralizing activity against the highly pathogenic
H5N1 influenza A virus [12]. The in vivo protection of
AVFluIgG01 against challenge by H5N1 virus highlights its
potential application as a therapeutic antibody or as a basis for
vaccine development. In both cases, characterizations of its
antigenic epitope and mechanism of neutralization is a key step.
In the present study, we have first demonstrated that the epitope of
AVFluIgG01 is a conformation-dependent and consists of three
discontinuous sites. The site I comprises three amino acids residues
(I116, I117, P118), while both of site II (W122, S123) and site III
(Y164, T167) comprise two amino acids. In the 3D structure of
H5N1 HA, these epitope residues are closely located at the tip of
the membrane-distal globular head of HA and neighbored with
the receptor-binding domain, which comprises the 190-helix (HA1
188 to 190), 130-loop (HA1 134 to 138) and 220-loop (HA1 221 to
228) as colored in red in Fig. 4B. Interestingly, although this region
is highly variable but all the epitope participatory residues are
highly conserved among diverse H5 clades and subclades. We
believe that this conservation could provide the basis for antibody
to exert its broad-spectrum anti-H5N1 activity.
Obviously, our present results differ from the previous data
reported by Sun et al [12]. The authors considered that the
AVFluIgG01 was directed against a linear epitope based on its
reactivity in the Western-blotting assay. The epitope was further
located within the amino acid sequence of
116IIPKSSWSS
124
based on the mutagenesis analysis. In our Western blotting assays
using both recombinant proteins and transfected cells as samples,
AVFluIgG01 did repeatedly react with the HA protein in the gels
(data not shown). In general view, the simplest way to determine
whether an epitope is conformational or linear is by immunoblot-
ting after SDS-PAGE [20]. If the antibody still binds after the
protein has been denatured, the epitope is unlikely to be highly
conformational. However, protein renaturation can occur after
SDS gel electrophoresis or after electroblotting, which may result
in an epitope refolded. In particular, a positive reaction on
immunoblots can also be achieved by non-linear epitopes where
the reacting portions are in relatively close proximity. In our
experiences, a panel of mouse mAbs against the spike protein of
SARS-CoV reacted with antigens on immunoblots but their
epitopes were conformation-dependent [21–23]. Therefore, the
AVFluIgG01 epitope might be such the case. The steric residues in
the three sites could be readily refolded through short-range
interactions to keep a ‘‘local’’ conformation. But the epitope could
not be refolded when the HA protein was treated by a reducing
reagent followed by blocking the reactive sites, thus resulting in the
loss of the reactivity in ELISA wells. Contradicting to the previous
conclusion, AVFluIgG01 could not recognize any of the synthe-
sized peptides that contain or overlap the proposed linear epitope
sequence (
116IIPKSSWSS
124). Taken together, the data strongly
suggested a conformation-dependent epitope for AVFluIgG01.
Therefore, we decided to map its contacting residues on the
surface of the HA tridimensional structure by using a random
Figure 2. Prediction of AVFluIgG01 epitope by minotopes. A. Affinity-selected minotopes from a random peptide phage display library. The
selection frequency of a specific minotope is shown in parentheses. B. Predicted amino acid residues by Mapitope. C. Predicted amino acid residues
by Pep-3D-Search. The common residues that are predicted by both algorithms are underlined and shown in bold.
doi:10.1371/journal.pone.0038126.g002
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site-directed mutations analyzed by flow cytometry. B. The reactivity of AVFluIgG01 with the WT (red curve) or HA carrying single mutations (green
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tional prediction and experimental verification.
Vaccination is considered to be the most efficient strategy to
combat the influenza A virus, but its continous antigenic drift and
occasional antigenic shift have significantly hampered the devel-
opment of an universal influenza vaccine [24–25]. For many years,
considerable efforts have been made to characterize the antigenic
epitopes of the HA protein, but much of the available information
pertains to antibodies generated from mice rather than humans
[9,26]. The frequent occurrence of highly pathogenic H5N1-
infected human cases and the recent outbreak of a novel swine-like
human H1N1 influenza virus have promoted the exploration of
natural-occurring human antibodies as therapeutics or for vaccine
design. In recent years, a number of human mAbs to H5N1
viruses have been generated from either immortalized human
memory B cells obtained from patients who recovered from H5N1
disease or with combinational antibody library technologies
[12,17,27–31]. It has been shown that some of these human
antibodies possess broad-spectrum H5N1-neutralizing activity or
cross-subtype reactivity to H1 viruses, and are highly effective in
suppressing H5N1 virus in experimentally infected animals when
administered prophylactically or therapeutically [12,25,28,31].
Importantly, antigenic characterizations of the newly-isolated anti-
H5N1 human mAbs have identified novel neutralizing epitopes in
HA protein and provided intriguing insights for universal influenza
vaccine development [12–13,17,19,25,28]. The best examples are
human mAbs CR6261 and F10, which possess broadly neutral-
izing activity and are directed against the highly conserved
epitopes in the HA2 subunit [19,25,28,31]. It is also impressive
that the epitope of AVFluIgG01 is overlapped by two other
epitopes recognized by human mAbs (FLA5.10 and FLD21.140)
that were isolated from the survivals of HPAI H5N1 in Vietnam
[27]. FLA5.10 recognized a conformational epitope containing the
residues
115QIIP
118 and
126EASL
129 and had a narrow (clade 1-
specific) neutralization range, while FLD21.140 recognized a
conformational epitope containing the residues
121SWS
123 and
164YNNT
167and had a relatively broader cross-clade neutraliza-
tion than the former [13,27]. During the preparation of this
manuscript, a new anti-H5N1 human mAb, 65C6 with the
neutralizing and protective activity has been reported by Hu et al
[17]. It was isolated from a surviving patient from H5N1 infection
in China, and mapped to a conformational epitope containing the
residues P118, S121, K161, Y164 and T167 [17]. Given that these
neutralizing human mAbs were isolated from different surviving
H5N1-infected patients in independent laboratories but reacted
with the overlapping epitopes that are closely located a similar
region on the surface of HA 3D structure, we believe that the
AVFluIgG01 epitope represents an immunodominant site during
natural infection and can be used for immunogen design to elicit
broad-spectrum neutralizing antibodies against highly pathogenic
H5N1 viruses.
While the antigenic epitopes of influenza virus have been
explored as a hotspot, mechanisms of neutralization by antibodies
are paid with much less attention. Actually, both aspects are
important for dissecting the structure and function of the HA
protein and thus for developing immunotherapeutics and vaccines
against influenza. In this study, we first demonstrated that
AVFluIgG01 could block both HA-mediated virus attachment
and postattachment steps, and then showed its direct inhibition on
HA-mediated cell-cell fusion and acquisition of pH-induced
protease sensitivity. The data suggest that AVFluIgG01 neutralizes
the virus through inhibiting not only receptor-binding but also
membrane fusion. In other word, both neutralization mechanisms
can occur simultaneously. This may not be so surprising to know
that this HA1-specific mAb can block two key steps for vial entry
and infection. The previous studies demonstrated that some HA1-
curve) analyzed by immuofluorescence assay (IFA). In both assays, the WT HA or mutants were transiently expressed on 293T cells by transfection and
then immunostanined by AVFluIgG01 or a control mAb at a final concentration of 10 mg/ml.
doi:10.1371/journal.pone.0038126.g003
Table 1. Reactivity of AVFluIgG01 with HA mutants.*
AVFluIgG01
Control
mAb
HA IFA FACS IFA FACS
Cells – – – –
WT +++ +++ +++ +++
N109A +++ +++ +++ +++
H110A +++ +++ +++ +++
E112A +++ +++ +++ +++
K113A +++ +++ +++ +++
I116A + + +++ +++
I117A + + +++ +++
P118A + + +++ +++
S120A +++ ++ +++ +++
S121A +++ +++ +++ +++
W122A –– +++ +++
S123A + + +++ +++
H125A +++ ++ +++ +++
S155A +++ +++ +++ +++
T156A +++ +++ +++ +++
S163A +++ +++ +++ +++
Y164A + + +++ +++
N165A +++ + +++ +++
T167A –– +++ +++
N168A +++ + +++ +++
Q169A +++ ++ +++ +++
Q192A +++ +++ +++ +++
N193A +++ +++ +++ +++
P194A +++ +++ +++ +++
S199A +++ +++ +++ +++
T202A +++ ++ +++ +++
S203A +++ +++ +++ +++
T204A +++ +++ +++ +++
Q207A +++ +++ +++ +++
N236A +++ ++ +++ +++
*The reactivity of AVFluIgG01 with HA and its mutants was tested at 10 mg/ml
by IFA and FACS respectively. ‘‘2’’ indicates negative reaction; ‘‘+, ++ and +++’’
indicate weak, medium, and strong positive, respectively. The bold mutants
indicate the residues critical for AVFluIgG01 binding.
doi:10.1371/journal.pone.0038126.t001
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similarly, although their specificity was concentration-dependent
event [32–33]. Interestingly, a recent study reported that HA1-
specific mouse anti-H5N1 mAb 9F4 was not able to block the
interaction between HA and its receptor but did block the virus
entry at the postattachment step. Consistently, 9F4 was further
shown to prevent the pH-mediated conformational change of HA.
Indeed, the neutralization of influenza viruses is highly complex
and multifaceted, and is governed by factors that include the virus
strain, the antigenic epitope, the antibody affinity and concentra-
tion, and the cells used [32].
It was notable that the Fab fragment of AVFluIgG01 could
not inhibit the receptor-binding step at a same concentration as
its IgG molecule (Fig. 5). In a sharp contrast, it could efficiently
block the membrane fusion step, as evidenced by its potent
inhibition on the viral entry after cell attachment (Fig. 6) and
on the HA acquisition of pH-induced protease sensitivity (Fig. 8).
Previous studies established that some HA1-specific Fabs
Figure 4. Surface representation of the AVFluIgG01 epitope on the globular head of HA trimer model (PDB ID: 2IBX). Amino acid
positions are designated in H5 numbering. A. Side view of the trimeric HA structure. The epitopic site I residues (I116, I117, P118) is colored in yellow,
and site II (W122, S123) and site III (Y164, T167) residues are colored in blue and green, respectively. B. Top view of the globular head. The region
encompassing the receptor binding site (RBS) is colored in red. C. Cartoon and sticks illustration of the three-dimensional structure of the AVFluIgG01
epitope. The diagram was generated with PyMOL.
doi:10.1371/journal.pone.0038126.g004
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differing from their IgGs [33–34]. On the other hand, some
HA1-specific Fabs neutralize by inhibiting virus attachment
only, but mechanism of neutralization by their IgGs is complex
and occurs simultaneously through fusion inhibition and
attachment inhibition [32]. Compared to HA1-specific mAbs,
HA2-specific mAbs, such as CR6261, neutralize the virus by a
mechanism of inhibiting membrane fusion activity exclusively
[19,28,35–36].
In summary, the significance of the present study is threefold.
First, it shows that AVFluIgG01 is directed against a novel and
conserved conformational epitope in the globular head of HA
protein. Second, the epitope residues have been finely mapped to
three discontinuous sites that are closely neighbored with the
receptor-binding domain. Third, AVFluIgG01 neutralizes the
virus by a mechanism of inhibiting the receptor-binding and
membrane fusion simultaneously. Our data have multiple
implications for developing effective immunotherapeutics and
vaccines against highly pathogenic H5N1 virus.
Materials and Methods
Antibodies, Peptides and Proteins
The generation and initial characterization of AVFluIgG01
and AVFluIgG03 were described previously [12]. Their
recombinant IgGs or Fab fragments were produced in insect
cells by the Sino Biological Inc, Beijing. CR6261, an human
anti-HA2 mAb was similarly produced in insect cells according
to the publications [31]. Mouse anti-HA2 (H5N1) mAb 9G1G9
was obtained from the Sino Biological Inc. HY498, an human
anti-HIV gp120 Fab was generated in our laboratory and used
as a control. A set of 77 overlapping peptides that span the
entire sequence of the HA protein of H5N1 strain A/H5N1/
Vietnam/1203/2004 (Viet04), range from 15–20 amino acids in
length, were synthesized at the SciLight Biotechnology LLC,
Beijing. Recombinant HA and HA1proteins derived from
Viet04 (Viet04-HA) or A/Common magpie/Hong Kong/
2256/2006 (HK06-HA) were purchased from the eENZYME
LLC (Gaithersburg, MD).
Figure 5. Inhibition of AVFluIgG01 on HA-mediated virus-receptor binding. The Viet04 HA pseudoviruses were preincubated with the
tested antibodies at 4uC overnight and subsequently added to MDCK cells for 2 hours at 4uC. The unbound viruses were washed off and the amount
of bound viruses was quantified. Binding was expressed as a percentage of the reading obtained in the absence of antibody (No Ab), which was set at
100%. A. AVFluIgG01 but not its Fab fragment or control mAbs (AVFluIgG03 and CR6261) inhibits the pseudovirus binding to MDCK cells at indicated
concentrations. B. AVFluIgG01 but not its Fab fragment inhibits the pseudovirus binding at a dose-dependent manner.
doi:10.1371/journal.pone.0038126.g005
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Reactivity of human (AVFluIgG01, AVFluIgG03 or HY498) or
mouse (9G1G9) mAbs with various HA antigens was determined
by ELISA. Briefly, 1 mg/ml recombinant Viet04-HA or HA1 or
5 mg/ml peptides were used to coat 96-well microtiter plates
(Costar, Corning, NY) in 0.1 M carbonate buffer (pH 9.6) at 4uC
overnight. The plates were blocked with 3% bovine serum
albumin (BSA) for 1 h at RT and then washed with PBS-0.05%
Tween 20 (PBST). A tested human or mouse mAb (diluted at
10 mg/ml) was added into wells and incubated at 37uC for 1 h,
followed by three washes with PBST. Bound antibodies were
detected with HRP-conjugated goat anti-human or mouse IgG
(Sigma, Aldrich) at 37uC for 1 h, followed by three washes. The
reaction was visualized by addition of 3,39,5,59-tetramethylbenzi-
dine (TMB) substrate (Sigma), and stopped by the addition of 2 M
H2SO4. The absorbance at 450 nm was measured by an ELISA
plate reader (Bio-Rad).
To determine the effect of disulfide bond reduction on the
binding of anti-HA mAbs, an ELISA plate was coated with
recombinant HK06-HA at a concentration of 1 mg/ml and then
treated with dithiothreitol (DTT) at a concentration of 10 mM for
1 h at 37uC, followed by washes. The plate wells were then treated
with 50 mM iodoacetamide for 1 h at 37uC. After washes, a
standard ELISA was performed as described above.
Biopanning and Selection of Random Peptide Library by
AVFluIgG01
A random phage display library (Ph.D-12), wherein the
displayed peptides (12-mer) are expressed fused to the N terminus
of gIII protein was purchased from New England Biolabs (Beverly,
MA). Affinity selection of the phage clones from the library was
Figure 6. Postattachment neutralization of AVFluIgG01 and its Fab fragment. The Viet04 HA pseudoviruses were allowed to attach to
monolayer MDCK cells at 4uC for 6 hours. The unbound viruses were washed off and the tested antibodies were added to the monolayer for 2 hours
at 4uC. Then, the cells were incubated at 37uC for 72 hours. The luciferase activity in the cell lysates was determined. Viral entry was expressed as a
percentage of the reading obtained in the absence of antibody (No Ab), which was set at 100%. A. AVFluIgG01 and its Fab as well as CR6261 inhibit
the viral entry at indicated concentrations. B. Both of AVFluIgG01 and its Fab inhibit the pseudovirus entry at a dose-dependent manner.
doi:10.1371/journal.pone.0038126.g006
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the microtiter wells were coated with 100 mg/ml AVFluIgG01 in
100 ml 0.1 M NaHCO3 buffer (pH 8.6) at 4uC overnight. The
coated wells were blocked with 0.5% BSA in NaHCO3 buffer for
at least 1 h at 4uC and then washed 6 times with TBST (TBS
+0.1% Tween-20). The phage library (1610
10) was added into the
coated wells and incubated at room temperature (RT) for 1 h.
After washing the plates 10 times with TBST, bound phages were
eluted with 0.2 M Glycine-HCl (pH 2.2) containing 1 mg/ml BSA
and neutralized with 1 M Tris-HCl (pH 9.1). The eluted phages
were amplified by infecting log-phage Escherichia coli ER2738, and
then concentrated by polyethylene glycol (PEG) precipitation. The
phages were titered and submitted to the second round of
selection. After three rounds of selection, the selected phage clones
were identified by single-strand DNA sequencing and target
specificity were confirmed by phage ELISA. Briefly, the microtiter
wells were coated with 100 mlo f2mg/ml of AVFluIgG01 and
blocked by 0.5% BSA. Affinity-selected phages were added to the
Figure 7. Inhibition of AVFluIgG01 on HA-mediated cell-cell fusion. A. AVFluIgG01 inhibits the low-pH induced cell-cell fusion in Vero cells
that were transfected with the plasmid encoding Viet04 HA protein (pViet04-HA). The cells were stained with crystal violet. (a) Control cells (no HA
transfection); (b) Positive control (without antibodies); (c) Treated with 50 mg/ml AVFluIgG01; (d) Treated with 50 mg/ml control mAb (AVFluIgG03). B.
AVFluIgG01 inhibits cell fusion between 293T effector cells and MDCK target cells at a dose-dependent manner. 293T cells were co-transfected with
pViet04-HA and pGAL4-VP16 and MDCK cells were transfected with pGal5-luc. After fusion induced by low-pH, the luciferase activity was measured in
the cell lysates. The percent inhibition and IC50 were calculated.
doi:10.1371/journal.pone.0038126.g007
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(0.5% Tween 20), HRP-conjugated murine anti-M13 antibodies
(Sigma) were added to the wells and incubated at 37uC for 1 h.
The wells were extensively washed with TBST and reacted with
TMB substrate (Sigma). Absorbance at 450 nm was measured
with an ELISA reader (Bio-Rad).
Computational Methods
Two web-available computer programs, Mapitope [15] and
Pep-3D-Search [16], were applied to predict the AVFluIgG01
epitope based on the selected peptides (mimotopes) from the
random phage display library. The algorithm of Mapitope is
based on the assumption that the epitope is separated into
several amino acid pairs (AAP) contributing for the binding to
the antibodies and the entire set of peptides is enriched with
AAP which mimic the genuine epitope. In Pep-3D-Search, a
promising ACO (Ant Colony Optimization) algorithm was
proposed to search matching paths on an antigen surface with
respect to the query mimotopes or a motif. Both tools are
validated for mapping a conformation-dependent epitope based
on the affinity-selected mimotopes.
Site-directed Mutagenesis
The plasmid pViet04-HA encoding a full-length HA of H5N1
(A/H5N1/Vietnam/1203/2004) was constructed and used as a
template. A panel of HA mutants (Table 1) were generated by site-
directed mutagenesis using the QuikChange XL kit (Stratagene,
La Jolla, CA). The primers used for construction of HA mutants
were designed and synthesized according to the manufacturer’s
instructions. The introduced mutations were verified by DNA
sequencing.
Figure 8. Inhibition of AVFluIgG01 on the pH-induced conformational changes of HA. The recombinant Viet04 HA proteins were
incubated with or without AVFluIgG01 (A) or its Fab (B)a t3 7 uC for 1 h. The mixture was either held at pH 7.5 (lanes 2, 4, 6 and 8) or changed to
pH 5.0 (lanes 1, 3, 5 and 7) at 37uC for 1 h. After the pH was restored to 7.5, trypsin (1 mg/ml) was added to detect the acquisition of pH-induced
protease susceptibility (lanes 5 to 8). The samples were then analyzed by western blotting. Molecular markers are given on the left.
doi:10.1371/journal.pone.0038126.g008
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The reactivity of AVFluIgG01 with wild-type (WT) HA or HA
containing mutations was measured by flow cytometry. Briefly,
293T cells were transiently transfected with a specific plasmid. The
transfected cells were harvested at 24 h after transfection and
washed two times with PBS containing 1% BSA. AVFluIgG01 or
a control mAb was added to the cells to a final concentration of
10 mg/ml and incubated at 4uC for 1 h. Cells were then washed
three times with PBS containing 1% BSA and incubated with
FITC-conjugated goat anti-human or anti-mouse IgG (Sigma) at
4uC for 1 h in the dark. After three washes, the cells were re-
suspended in cold PBS and analyzed by Becton Dickinson
FACScalibur (Becton Dickinson, Franklin Lakes, NJ).
Immuofluorescence Assay (IFA)
The plasmids encoding HA (WT or mutants) were transiently
expressed in 293T cells by transfection. After 24 hours, cells were
directly stained in the wells. Briefly, the cells were first fixed by 4%
paraformaldehyde in PBS (pH 7.4) for 15 min at RT, followed by
three washes with PBS. The cells were then incubated with 1%
BSA in PBST for 30 min to block unspecific binding of the
antibodies. AVFluIgG01 or a control mAb was added to the cells
at a final concentration of 10 mg/ml and incubated at RT for 1 h
in a humidified chamber. After washes, bound antibodies were
detected by using FITC-conjugated anti-human antibodies and
observed under an immunofluorescence microscope.
Virus Binding Inhibition Assay
The virus binding assay was performed using HA (Viet04)-
pseudotyped HIV viruses as described previously [28,37]. Briefly,
the HA pseudoviruses were generated by co-transfection of 293T
cells with the plasmid pViet04-HA, and a plasmid encoding NA
protein of A/H5N1/Tailand/1(KAN-1)/2004 and a backbone
plasmid encoding Env-defective, luciferaseexpressing HIV-1
genome (pNL4-3.luc.RE). The pseudoviruses were first incubated
with tested antibody (AVFluIgG01 and its Fab fragment or control
mAbs) diluted in DMEM containing 1% BSA at 4uC overnight.
MDCK cells were seeded in 24-well plates and grew 24 h at a
monolayer and then blocked with DMEM containing 1% BSA at
4uC for 1 h. The mixture of pseudoviruses and antibody was
inoculated onto MDCK cells and incubated at 4uC for 2 h. Cells
were rinsed four times with PBS containing 1% BSA to remove
unbound viruses. Then, the cells were lysed in 250 ml of DMEM
using a freeze-thaw method. The amount of cell-bound viruses in
the presence or absence of antibodies was quantified by an HIV-1
p24 ELISA kit (Vironostika HIV-1 antigen microelisa system,
Biomerieux). Percent inhibition and 50% inhibitory concentration
(IC50) were calculated.
Postattachment Neutralization Assay
The postattachment assay was performed as previously
described [33,37]. Briefly, HA-pseudoviruses were inoculated onto
an MDCK monolayer in a 96-well plate at 4uC for 6 h. The
unbound viruses were removed by washing with cold PBS. A
tested antibody was serially diluted and added to the monolayer at
4uC for 2 h. The antibody was then removed by washing, and
fresh DMEM was added to the monolayer before incubation at
37uC. After 72 h infection, the luciferase activity of the cells was
measured by using the luciferase assay system (Promega, Madison)
according to the manufacturer’s instructions. Percent inhibition
and IC50 were calculated.
Inhibition of Cell-cell Fusion
A cell fusion inhibition assay was performed as described
previously [28]. In brief, Vero cells were grown at ,90%
confluent in 12-well plates and transfected with pViet04-HA
plasmid (1.6 mg total DNA per well) using lipofectamine 2000
(Invitrogen) according to the instruction manual. After 24 hours of
transfection, the culture medium was supplemented with 50 mg/
ml of AVFluIgG01 or a control mAb for 1 h. After washing three
times by PBS (pH 7.4), cells were incubated with low-pH fusion-
inducing buffer (150 mM NaCl +10 mM HEPES, adjusted to
pH 5.0) for 5 mins, and then returned to the standard culture
medium for 2 hours at 37uC. Finally, cells were fixed with 4%
polyoxymethylene and stained with 0.5% crystal violet for
20 mins.
To quantitatively analyze the inhibitory effect of AVFluIgG01
on HA-driven cell-cell fusion, a sensitive assay was adapted from
our previous studies [38–39]. Briefly, 293T effector cells seeded in
48-well plates at 0.8610
5 cells per well were transfected with
pViet04-HA in combination with plasmid pGAL4-VP16, which
encodes the herpes simplex virus VP16 transactivator fused to the
DNA binding domain of the Saccharomyces cerevisiae transcription
factor GAL4. In parallel, MDCK target cells were transfected with
plasmid pGal5-luc, which encodes the luciferase reporter gene
under the control of a promoter containing five GAL4 binding
sites. The day after transfection, effector cells were incubated with
various concentrations of tested antibodies diluted in serum-free
medium (OPTI-MEM)at 37uC for 1 h. After washes, the effector
cells were treated with low-pH fusion inducing buffer (same as
above) for 5 mins and added to the target cells. After co-culturing
for an additional 48 h, the cells were lysed by cell culture lysis
buffer, and the luciferase activity was measured by luciferase assay
system (Promega). The percent inhibition and IC50 were
calculated.
Protease Susceptibility Assay
The protease susceptibility assay was adapted from the
previous studies [19,33,37]. In brief, 2 mg of HA protein
(Viet04) was incubated with AVFluIgG01 or its Fab at 37uC for
1 h. The neutralization mixture was then kept at pH 7.5 or
lowered to pH 5.0 by addition of 0.1 M HCl and incubated at
37uC for 1 h. The pH of the mixture was then restored to
neutrality (pH 7.5) by addition of 0.1 M Tris (pH 10). The
change of the HA to the low-pH conformation was detected by
incubation with trypsin (1 mg/ml) at 37uC for 1 h. Reaction was
stopped by addition of non-reducing SDS loading buffer and
was further analyzed by Western blotting. Briefly, the digested
mixture was fractionated by 10% SDS-PAGE under reducing
conditions. The separated proteins were electrotransferred and
immobilized on a PVDF membrane. After blocked with 5%
nonfat milk in PBS at 4uC overnight, the membrane was
incubated with a mouse anti-HA mAb (specific for HA1) at
37uC for 1 h, followed by washes with PBS. HRP-conjugated
goat anti-mouse IgG was added and incubated at RT for 1 h.
The membrane was washed and incubated with ECL reagents
(Pierce).
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